AU-565 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	AU-565 is a human breast adenocarcinoma cell line established in the mid-1980s at the Naval Biosciences Laboratory. The cell line was derived from a malignant pleural effusion in a 43-year-old Caucasian female patient who had previously undergone treatment with radiation therapy, corticosteroids, cyclophosphamide, and 5-fluorouracil. AU-565 and its parallel cell line, SK-BR-3—both originating from the same patient—together constitute one of the most widely cited models for HER2-positive breast cancer. These cells grow as an adherent epithelial monolayer with a doubling time of approximately 46 hours. Classified as the "HER2-enriched" subtype, AU-565 exhibits high-level amplification and overexpression of the HER2/ERBB2 gene; the cells test strongly positive for HER2, HER3, HER4, and p53, while testing negative for estrogen and progesterone receptors. The cell line harbors a homozygous TP53 p.R175H hotspot mutation and is microsatellite stable. AU-565 and SK-BR-3 are frequently used as a paired model for HER2-amplified breast cancer in three-dimensional spheroid culture experiments and in vivo xenograft studies to evaluate HER2-targeted therapies. Furthermore, they are commonly included in breast cancer gene expression profiling studies and CRISPR-based screens for target prioritization.
Tissue	Pleural effusion (metastatic)
Disease	Breast Adenocarcinoma; HER2-enriched subtype
Morphology	Epithelial
Gender	Female
Age	43 years
Ethnicity	Caucasian
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification is based on U.S. Public Health Service Guidelines)
Applications	1. HER2-targeted therapy studies, including trastuzumab and trastuzumab-derivative sensitivity and resistance 2. Breast cancer molecular subtype biology and HER2-enriched gene expression profiling 3. Investigation of HER2, HER3 and HER4 receptor signaling and ligand (heregulin/NDF) responses 4. Three-dimensional culture morphology and in vivo drug response studies 5. Glutamine metabolism and xCT antiporter dependency in HER2-positive breast cancer 6. Functional genomic and CRISPR target-prioritization studies in breast cancer
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Doubling Time	Approximately 46 hours
Genetic Profile	HER2/ERBB2 amplification and overexpression; TP53 p.R175H (c.524G>A), homozygous
Expression Markers	Strongly positive for HER2 (ERBB2), HER3 (ERBB3), HER4 (ERBB4), p53 and EGF. Negative for estrogen receptor (ER) and progesterone receptor (PR)
Mycoplasma Test	Negative
Culture Conditions and Handling
Subculturing	1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes). 4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels.
Medium Renewal	2 to 3 times per week
Subcultivation Ratio	A split ratio of 1:2 to 1:4 is recommended when the monolayer reaches 70–80% confluence.
Culture Conditions	Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation	Complete growth medium supplemented with 5% (v/v) DMSO

Cat.No.	Product Name	Price
CSC-RO0218	Cas9 Stable Cell Line - AU-565	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry